-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 13th, the CDE official website showed that the application for the clinical trial of the recombinant humanized anti-Trop2 monoclonal antibody-SN38 conjugate of Shijian Bio/Toyo Pharmaceutical Co.
At present, no ADC drug for this target has been approved for marketing in China.
Kelun Botai, Duoxi Biotech, Fudan Zhangjiang, Biotech have also declared the target ADC.
At present, there are more than 50 ADC drugs declared clinically in China, involving targets including HER2, TROP-2, CD30, c-Met, etc.